Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 9, 2021
Product Development

Feb. 8 Quick Takes: FDA approves TG’s lymphoma therapy; plus uniQure, Astellas, BMS, Viiv, Avrobio and Veru

FDA approved Ukoniq umbralisib from TG Therapeutics Inc. (NASDAQ:TGTX) to treat relapsed or refractory marginal zone lymphoma following anti-CD20 treatment, or relapsed or refractory follicular
BioCentury | Sep 8, 2017
Finance

Verastem’s value play

How Verastem parlayed duvelisib deal into a $54 million market cap bump
Items per page:
1 - 3 of 3
Help Center
Username
Request a Demo
Request Training
Ask a Question